BSE: 532039 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zenotech Laboratories Ltd is a average quality company.
The key valuation ratios of Zenotech Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenotech Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -61.5% | -65.7% | 0% | -61.9% | -6% | 18.3% | 0.5% | 15.3% | 18.4% | 12.9% | - |
| Value Creation Index ⓘ | NA | NA | NA | -5.4 | -1.4 | 0.3 | -1.0 | 0.1 | 0.3 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 4.1 | 2.1 | 2.3 | 11.1 | 13 | 26 | 22.5 | 36.6 | 42.4 | 40.8 | 36 |
| Sales YoY Gr. | - | -49.5% | 9.2% | 395.1% | 17% | 99.7% | -13.7% | 62.9% | 16% | -3.8% | - |
| Adj EPS ⓘ | -8.4 | -5.2 | -5.8 | -1.9 | -0.5 | 1 | -0.2 | 3.6 | 1.9 | 1.4 | 1.1 |
| YoY Gr. | - | NA | NA | NA | NA | NA | -119.2% | NA | -47.9% | -28% | - |
| BVPS (₹) ⓘ | -7.5 | -12.7 | -18.2 | 6.9 | 6.4 | 8.1 | 7.9 | 11.6 | 13.5 | 14.8 | 15.3 |
| Adj Net Profit ⓘ | -30.3 | -18.9 | -21.1 | -11.8 | -3 | 6.3 | -1.2 | 22.2 | 11.6 | 8.3 | 7 |
| Cash Flow from Ops. ⓘ | -7.7 | -4.8 | 1.6 | -16.3 | -14 | 11.4 | 5.7 | 17.7 | 20.7 | 11.8 | - |
| Debt/CF from Ops. ⓘ | -7 | -11.3 | 33.2 | 0 | -1.4 | 1.6 | 3.6 | 0.3 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 29.2% | 25.7% | 22.1% | -3.8% | ||||
| Adj EPS ⓘ | NA | NA | NA | -28% | ||||
| BVPSⓘ | NA | 18.4% | 23.2% | 10.1% | ||||
| Share Price | 12.5% | 22.6% | 23.5% | 13.5% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 252.8 | 51.6 | 37.7 | 99.2 | -7.5 | 14.3 | -2.5 | 37.3 | 15.1 | 9.6 | 7.2 |
| Op. Profit Mgn % ⓘ | -488.2 | -372.5 | -460.4 | -70.5 | -26 | 34.5 | 28.4 | 47.8 | 48.8 | 42.3 | 38.9 |
| Net Profit Mgn % ⓘ | -743.6 | -917.4 | -937.4 | -106.3 | -23.3 | 24.3 | -5.4 | 60.7 | 27.3 | 20.4 | 18.7 |
| Debt to Equity ⓘ | -2 | -1.2 | -0.8 | 0 | 0.5 | 0.4 | 0.4 | 0.1 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 543 | 842 | 610 | 148 | 239 | 125 | 111 | 76 | 78 | 100 | 151 |
| Cash Conv. Cycle ⓘ | 186 | 252 | 106 | -70 | -42 | -44 | -9 | 9 | -6 | -7 | 81 |
Sales growth is growing at healthy rate in last 3 years 22.06%
Return on Equity has declined versus last 3 years average to 7.20%
Sales growth is not so good in last 4 quarters at -0.03%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.1 | -2.1 |
| TTM Sales (₹ Cr.) | 35.7 | 6.6 |
| BVPS (₹.) ⓘ | 15.3 | 0 |
| Reserves (₹ Cr.) ⓘ | 32 | 62 |
| P/BV ⓘ | 4.99 | 0.00 |
| PE ⓘ | 69.75 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 52.23 / 107.79 |
| All Time Low / High (₹) | 3.99 / 173.59 |
| Market Cap (₹ Cr.) | 464 |
| Equity (₹ Cr.) | 61 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 2 | 2 | 11 | 13 | 26 | 22 | 37 | 42 | 41 |
| Operating Expenses ⓘ | 24 | 10 | 13 | 19 | 17 | 17 | 16 | 19 | 22 | 24 |
| Manufacturing Costs | 2 | 2 | 5 | 9 | 8 | 9 | 8 | 10 | 11 | 11 |
| Material Costs | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Employee Cost | 3 | 2 | 3 | 5 | 5 | 6 | 6 | 7 | 8 | 9 |
| Other Costs ⓘ | 15 | 4 | 3 | 4 | 3 | 2 | 2 | 2 | 2 | 3 |
| Operating Profit ⓘ | -20 | -8 | -10 | -8 | -4 | 9 | 6 | 17 | 21 | 17 |
| Operating Profit Margin (%) | -491.0% | -389.0% | -461.0% | -70.6% | -27.0% | 34.5% | 28.4% | 47.8% | 48.8% | 42.2% |
| Other Income ⓘ | 0 | 0 | 0 | 2 | 5 | 1 | 0 | 1 | 1 | 1 |
| Interest ⓘ | 7 | 8 | 8 | 2 | 0 | 1 | 2 | 1 | 0 | 0 |
| Depreciation ⓘ | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 |
| Exceptional Items ⓘ | 0 | 0 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 10 | 15 | 11 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | 3 | 3 |
| Profit After Tax | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 22 | 12 | 8 |
| PAT Margin (%) | -746.0% | -929.0% | -881.0% | -106.0% | -24.0% | 41.4% | -5.4% | 60.6% | 27.3% | 20.3% |
| Adjusted EPS (₹) | -8.4 | -5.3 | -5.5 | -1.9 | -0.5 | 1.8 | -0.2 | 3.6 | 1.9 | 1.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | -27 | -46 | -66 | 42 | 39 | 50 | 48 | 71 | 82 | 91 |
| Share Capital ⓘ | 34 | 34 | 34 | 61 | 61 | 61 | 61 | 61 | 61 | 61 |
| Reserves ⓘ | -62 | -80 | -100 | -19 | -22 | -11 | -13 | 10 | 21 | 30 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 51 | 51 | 51 | 0 | 20 | 19 | 21 | 6 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 6 | 0 | 0 |
| Short Term Debt | 51 | 51 | 51 | 0 | 20 | 19 | 0 | 0 | 0 | 0 |
| Trade Payables | 2 | 4 | 5 | 5 | 4 | 5 | 2 | 2 | 3 | 3 |
| Others Liabilities ⓘ | 38 | 44 | 60 | 34 | 21 | 13 | 15 | 3 | 6 | 6 |
| Total Liabilities ⓘ | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 | 92 | 100 |
Fixed Assets | ||||||||||
| Gross Block | 83 | 52 | 55 | 56 | 59 | 70 | 101 | 105 | 107 | 114 |
| Accumulated Depreciation | 29 | 4 | 8 | 12 | 16 | 21 | 27 | 34 | 41 | 48 |
| Net Fixed Assetsⓘ | 53 | 48 | 47 | 44 | 43 | 49 | 74 | 71 | 65 | 66 |
| CWIP ⓘ | 0 | 0 | 0 | 2 | 17 | 29 | 2 | 0 | 5 | 2 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Trade Receivables | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 4 | 3 | 3 |
| Cash Equivalents | 6 | 0 | 1 | 29 | 13 | 1 | 2 | 2 | 11 | 20 |
| Others Assetsⓘ | 2 | 2 | 2 | 5 | 8 | 5 | 3 | 4 | 7 | 8 |
| Total Assets ⓘ | 64 | 53 | 51 | 82 | 85 | 86 | 86 | 82 | 92 | 100 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -8 | -5 | 2 | -16 | -14 | 11 | 6 | 18 | 21 | 12 |
| PBT ⓘ | -30 | -19 | -20 | -12 | -3 | 11 | -1 | 10 | 15 | 11 |
| Adjustment ⓘ | 11 | 12 | 10 | 5 | 0 | -2 | 8 | 8 | 7 | 6 |
| Changes in Working Capital ⓘ | 12 | 2 | 12 | -9 | -10 | 3 | -1 | 1 | 0 | -4 |
| Tax Paid ⓘ | 0 | 1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 |
| Cash Flow From Investing Activity ⓘ | 0 | 5 | -1 | -3 | -16 | -21 | -5 | -2 | -6 | -21 |
| Capex | 0 | 0 | -1 | -4 | -18 | -22 | -5 | -2 | -6 | -4 |
| Net Investments | 0 | 5 | 0 | -1 | 1 | 0 | 0 | 0 | 0 | -18 |
| Others ⓘ | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 |
| Cash Flow From Financing Activityⓘ | 7 | -1 | -1 | 47 | 15 | -3 | 0 | -16 | -6 | 0 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 120 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | -3 | 0 | -12 | 0 | -15 | -6 | 0 |
| Interest Paid ⓘ | -1 | -1 | -1 | -19 | -5 | -1 | -2 | -1 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 7 | 0 | 0 | -51 | 20 | 10 | 2 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | -1 | 0 | 0 | 28 | -15 | -12 | 1 | 0 | 9 | -9 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | N/A | N/A | 0 | -7.73 | 24.35 | -2.48 | 37.26 | 15.15 | 9.6 |
| ROCE (%) | N/A | N/A | N/A | -61.88 | -5.95 | 18.32 | 0.48 | 15.26 | 18.39 | 12.89 |
| Asset Turnover Ratio | 0.07 | 0.04 | 0.04 | 0.17 | 0.16 | 0.31 | 0.26 | 0.44 | 0.49 | 0.43 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | 1 | N/A | 0.82 | 1.75 | 1.5 | Working Capital Days |
| Receivable Days | 20 | 62 | 28 | 0 | 33 | 30 | 46 | 39 | 31 | 29 |
| Inventory Days | 240 | 302 | 203 | 29 | 20 | 5 | 1 | 1 | 0 | 8 |
| Payable Days | 303 | 594 | 1,026 | 2,410 | 2,424 | 3,154 | 0 | 0 | 0 | 0 |
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.
The company aims to bring a constant pipeline of new biogeneric products to the market. The highly qualified and trained staff uses recombinant DNA technology and cGMP production methods to give the customers generic versions of biotherapeutic drugs comparable to the innovator product in quality, safety and efficacy.
Zenotech’s technical staff are well versed in gene cloning and expression, fermentation, downstream processing, protein purification, process validation and manufacture of recombinant DNA products from bacterial, yeast and mammalian cells.
Zenotech has a full fledged research and development facility for generating recombinant proteins for clinical development. The company plans to set up cGMP manufacturing facilities that will house multiple fermentors, bioreactors and chromatography systems to meet the demands of the Indian and other emerging markets.
Zenotech develops new biological entities in the areas of cancer and neurology. The company has initiated target identification and validation programs using gene and protein based technologies. This brings together proprietary technologies in the identification of cell surface proteins and receptors as candidate drug targets.
Zenotech utilizes validated targets for generating new therapeutic entites. The company plans to adopt a comprehensive approach to therapeutic monoclonal antibody generation by bringing together skills in the areas of recombinant DNA technology, protein purification and characterization in the development of new antigen and antibody-based therapeutics for clinical studies.
Zenotech offers comprehensive services for generating and characterizing recombinant proteins. The company provides a full range of services from cloning a gene, expression in microbial or mammalian systems, process development and generation of milligram to gram quantities of pure recombinant proteins. The company also offers functional, validated assays in both cell-based and cell-free formats for use in drug discovery.
Product range of the company includes:
Generics -- Biological
Chemical
New biologicals Zenotech develops new biological entities in the areas of
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
